

## ASX RELEASE



ASX Code: ESE

19 February 2018

### TREATMENT OF CONVERTED CLASS C PERFORMANCE RIGHTS

Life sciences company **eSense-Lab Ltd** (“**eSense**” or the “**Company**”) (**ASX: ESE**) makes the following announcement in relation to the 9,537,503 CDIs and 6,429,111 Class E Performance Rights that were issued on or about 29 January 2018 upon conversion of 9,537,503 Class C Performance Rights.

As per the Company’s letter released to the market on 7 February 2018, the Board of the Company is satisfied that these Class C Performance Rights were converted into CDIs and Class E Performance Rights in accordance with their terms of issue and that the Board acted properly in authorising their conversion.

However, on 8 February 2018, the Board resolved to cancel the conversion of the Class C Performance Rights and issue of the Class E Performance Rights. In order to avoid certain logistical constraints and expedite the effectiveness of the Board resolution, the holders have agreed to place the applicable CDIs and Class E Performance Rights in trust (while waiving all rights arising from such securities) in order to effectuate the Board’s decision.

The applicable CDIs and Class E Performance Rights will be held in trust until the earlier to occur of (i) a resolution of an authorized body of the Company to release such securities from the trust, or (ii) the Company receiving AUD \$1,000,000 pursuant to binding distribution contracts for the Company’s reconstructed terpene profiles signed by the Company between February 10, 2017 and February 10, 2018.

---

#### FOR FURTHER INFORMATION:

Ian Pamensky  
Company Secretary  
+61 414 864 746

[Investor/media relations](#)  
Matthew Wright  
+61 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

#### About eSense-Lab

eSense-Lab Ltd (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense-Lab can then use this model to ‘reverse engineer’ a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant’s health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost

To learn more about eSense-Lab, visit [www.esense-lab.com](http://www.esense-lab.com)